TMPRSS2 and prostate cancer: More recently, a novel fusion event was reported in about 1% of prostate cancer cases, juxtaposing exons 1 or 2 of TMPRSS2 to exon 2 of the SMAD inhibitor and oncogenic factor SKIL and leading to its overexpression.